NO990097L - Ny behandling av leptin-resistens - Google Patents

Ny behandling av leptin-resistens

Info

Publication number
NO990097L
NO990097L NO990097A NO990097A NO990097L NO 990097 L NO990097 L NO 990097L NO 990097 A NO990097 A NO 990097A NO 990097 A NO990097 A NO 990097A NO 990097 L NO990097 L NO 990097L
Authority
NO
Norway
Prior art keywords
leptin resistance
new treatment
leptin
pharmaceutically acceptable
resistance
Prior art date
Application number
NO990097A
Other languages
English (en)
Norwegian (no)
Other versions
NO990097D0 (no
Inventor
George Henry Poste
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614751.7A external-priority patent/GB9614751D0/en
Priority claimed from GBGB9614740.0A external-priority patent/GB9614740D0/en
Priority claimed from GBGB9616407.4A external-priority patent/GB9616407D0/en
Priority claimed from GBGB9616409.0A external-priority patent/GB9616409D0/en
Priority claimed from GBGB9616412.4A external-priority patent/GB9616412D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO990097L publication Critical patent/NO990097L/no
Publication of NO990097D0 publication Critical patent/NO990097D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO990097A 1996-07-12 1999-01-11 Ny behandling av leptin-resistens NO990097D0 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9614751.7A GB9614751D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9614740.0A GB9614740D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9616407.4A GB9616407D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616409.0A GB9616409D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616412.4A GB9616412D0 (en) 1996-08-05 1996-08-05 Novel treatment
PCT/GB1997/001928 WO1998002159A1 (en) 1996-07-12 1997-07-14 Novel treatment of leptine resistance

Publications (2)

Publication Number Publication Date
NO990097L true NO990097L (no) 1999-01-11
NO990097D0 NO990097D0 (no) 1999-01-11

Family

ID=27517363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990097A NO990097D0 (no) 1996-07-12 1999-01-11 Ny behandling av leptin-resistens

Country Status (12)

Country Link
EP (1) EP0921798A1 (xx)
JP (1) JP2000514807A (xx)
KR (1) KR20000023719A (xx)
CN (1) CN1230114A (xx)
AU (1) AU3552697A (xx)
BR (1) BR9710272A (xx)
CA (1) CA2260044A1 (xx)
NO (1) NO990097D0 (xx)
PL (1) PL331148A1 (xx)
TR (1) TR199900056T2 (xx)
TW (1) TW442288B (xx)
WO (1) WO1998002159A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
AU2893199A (en) * 1998-03-03 1999-09-20 Board Of Regents, The University Of Texas System Fatty acid-induced beta-cell apoptosis
EP1175412A1 (en) 1999-04-28 2002-01-30 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
ATE423559T1 (de) * 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
DK2712617T3 (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
MX2009007728A (es) 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
KR101789960B1 (ko) 2008-11-19 2017-10-25 인터셉트 파마슈티컬즈, 인크. Tgr5 조절제 및 그의 사용 방법
CN104781272A (zh) 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AU2479492A (en) * 1991-08-26 1993-03-16 Upjohn Company, The Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
PL331148A1 (en) 1999-06-21
AU3552697A (en) 1998-02-09
BR9710272A (pt) 1999-08-10
EP0921798A1 (en) 1999-06-16
CN1230114A (zh) 1999-09-29
WO1998002159A1 (en) 1998-01-22
JP2000514807A (ja) 2000-11-07
NO990097D0 (no) 1999-01-11
TW442288B (en) 2001-06-23
TR199900056T2 (xx) 1999-04-21
CA2260044A1 (en) 1998-01-22
KR20000023719A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
NO990097L (no) Ny behandling av leptin-resistens
MX9704793A (es) Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina.
HK1006810A1 (en) Compositions comprising omega conotoxin peptide derivatives and their use for treating ischemia-related neuronal damage
NO20012978L (no) Fremgangsmåte og preparater for behandling av alvorlig bronkitt med et aerosolisert antibiotikum
PL316007A1 (en) Vaccine based on urease and method of treating infections caused by heliobacter
BG100960A (en) Dosage forms for controlled release of azitromycin
TJ270B (en) 5,6-Dichlorobenzimidazole derivatives process for their preparation pharmaceutical composition and method of treatment or prophylaxis of virus infections
GB9822440D0 (en) Medicaments
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
SE9603725D0 (sv) New teatment
EP1911446A3 (en) The use of PPAR-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired plasticity
MY122838A (en) Treating allergic and inflammatory conditions
ID27276A (id) Oksazolidinon-oksazolidinon untuk merawat infeksi-infeksi mata
IL126539A (en) Pregnane derivatives with no alpha-17 substituent, their medicinal use and manufacturing method
WO2002036124A3 (en) Treatment and method using loratadine and montelukast
WO2001041755A3 (en) Topical compositions comprising thalidomide for the treatment of inflammatory diseases
MY130725A (en) Composition and method for treating allergic diseases
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
PT1156795E (pt) Utilizacao de acido succinico ou de seus sais e metodo de tratamento da resistencia a insulina
EP0456842A4 (en) Medicinal application of m-csf
PT1140080E (pt) Utilizacao de riluzole no tratamento de traumatismos acusticos
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
BR0013655A (pt) Uso de uma proteìna histacalina, e, método de tratamento ou de prevenção de rinite alérgica
NO985325L (no) Anvendelse av substituert azaspiran ved behandling av astma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application